ROIVANT SCIENCES LTD

Roivant Sciences faces a high‑risk, high‑reward quarter: with brepocitinib’s 2026 DM launch on track, investors weigh diversified R&D, legal wins, and cash flow challenges.

Roivant Sciences, a biotechnology company, continues to make significant strides in the healthcare industry through its innovative solutions and strategic partnerships, with a focus on transformative medicines and technologies to address pressing me…

Roivant Sciences Ltd. has seen a significant surge in its stock price following a series of positive clinical milestones, including a Phase III success for its autoimmune disease treatment, and a target price hike to $20.00 by analyst H.C. Wainwrigh…

Roivant Sciences Ltd (ROIV) shares surged 11-12% on September 17, 2025, driven by positive clinical data from its brepocitinib and rare disease studies, as well as a revised analyst price target of $20.

Roivant Sciences Ltd. saw its stock price surge 11-12% after reporting positive clinical trial results for its investigational drug Brepocitinib, leading to a higher valuation target from analysts.

Roivant Sciences Ltd. (ROIV) stock surged 12% to $15.28 on Wednesday, driven by positive clinical trial results and an analyst upgrade from Goldman Sachs, which lifted its target price to $24.00.

Roivant Sciences Ltd. is experiencing a surge in market momentum, driven by analyst endorsements, technical strength, and bullish options activity, positioning the biotech firm for potential growth and increased investor attention.

Roivant Sciences Ltd has made a groundbreaking discovery in Graves’ disease treatment, with its novel compound batoclimab showing promising results in achieving remission without the need for anti-thyroid drugs in approximately 50% of patients.

Roivant Sciences reported a 87% revenue increase in Q4 2025, but missed earnings expectations, with a GAAP EPS of -$0.29 and revenue of $7.57 million.

Roivant Sciences Ltd is set to release its Q4 2025 earnings on May 29, 2025, with analysts expecting a mixed bag of results, including a revenue surge but a loss per share.